Algernon Pharmaceuticals
May 26, 2020
Algernon’s NP-120; FDA nod to 4DMedical tool; SaNOtize’s NORSTM trial; Pole’s capital increase
Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19. The company has submitted the IND with the US FDA for its planned multinational Phase 2b/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
